CSL Ltd. (ASX:CSL) said it agreed to pay $64 million to settle multi-district litigation accusing it of taking part in a price-fixing scheme for plasma therapy.
A federal judge granted Baxter‘s (NYSE:BAX) bid to force an FDA official to testify in the multi-district litigation accusing it of taking part in a price-fixing scheme for plasma therapy.